Hereditary pheochromocytoma-paraganglioma is a genetic condition that causes hormone-producing tumors in the adrenal glands or along nerve tissue. These tumors can release extra adrenaline-like hormones and cause high blood pressure, headaches, sweating, and fast heartbeat. Many people first hear about Hereditary pheochromocytoma-paraganglioma when a family member is diagnosed. It is lifelong, may appear in childhood or adulthood, and risks vary by the specific gene. Treatment usually involves surgery and careful blood pressure control, and with expert care most people do well, though rare aggressive tumors can affect survival.
Overview
Hereditary pheochromocytoma-paragangliomaSymptoms
Hereditary pheochromocytoma-paraganglioma features sudden adrenaline-like spells: pounding heartbeat, severe headache, sweating, shaking, and high blood pressure. Some notice chest pain, paleness, or anxiety. Head or neck tumors may cause a painless neck lump or a pulsing whoosh in one ear.
Outlook and prognosis
Many living with hereditary pheochromocytoma-paraganglioma do well when tumors are found early and managed by an experienced team. Regular imaging and lab checks help catch growth or recurrence before complications arise. Lifelong follow-up reduces risks, including high blood pressure crises and rare spread.
Causes and risk factors
Hereditary pheochromocytoma-paraganglioma most often stems from inherited gene changes; some cases arise as new mutations. Risk factors for hereditary pheochromocytoma-paraganglioma include a family history, certain related syndromes, and prolonged low-oxygen exposure; lifestyle seldom causes it but can influence complications.
Genetic influences
Genetics play a central role in hereditary pheochromocytoma-paraganglioma; most cases result from inherited variants in genes like SDHB, SDHD, VHL, RET, or NF1. These variants raise tumor risk, influence where tumors appear, and guide screening. Family testing is recommended.
Diagnosis
Doctors suspect it from clinical features and family history, then check blood or urine metanephrines. Imaging (MRI/CT, sometimes MIBG or PET) locates tumors. Genetic tests confirm the genetic diagnosis of Hereditary pheochromocytoma-paraganglioma and guide family screening.
Treatment and drugs
Treatment for hereditary pheochromocytoma-paraganglioma centers on careful tumor control and preventing hormone surges. Plans often include alpha- then beta-blockers to stabilize blood pressure, surgery to remove tumors, and targeted options like radiopharmaceuticals or focused radiation when needed. Regular imaging and lab monitoring guide timing and safety.
Symptoms
Sudden surges of stress hormones are a common driver of the signs people notice with hereditary pheochromocytoma-paraganglioma. These bursts can come and go or linger, and they may be brought on by exertion, stress, or even seemingly out of the blue. Early features of hereditary pheochromocytoma-paraganglioma include episodes of racing heartbeat, throbbing headache, heavy sweating, and pale or flushed skin. Features vary from person to person and can change over time.
Blood pressure may stay high or surge in sudden episodes. In hereditary pheochromocytoma-paraganglioma, spikes can be severe and may resist usual medicines. This often worsens during attacks or physical strain.
Throbbing or pressure-like headaches can strike without warning. They often accompany blood pressure surges and can last minutes to hours. Light or sound sensitivity may occur.
Sudden, heavy sweating can soak clothing or sheets. With hereditary pheochromocytoma-paraganglioma, sweats often pair with a racing heart or tremor. They may follow stress or exertion.
A pounding or racing heart can feel like fluttering or hard thumps. In hereditary pheochromocytoma-paraganglioma, this often comes in bursts that build and fade. Shortness of breath or chest discomfort can accompany it.
How people usually first notice Hereditary pheochromocytoma-paraganglioma?
Many first notice something is off when sudden “adrenaline rush” episodes hit without a clear trigger: pounding headaches, racing heartbeat, sweating, pallor or flushing, shakiness, and spikes in blood pressure that can cause dizziness or chest pain. Others first come to attention because a painless neck, skull-base, or abdominal mass is found on exam or imaging, or because an incidental tumor shows up on a scan done for another reason. In families with known risk, the first signs of hereditary pheochromocytoma-paraganglioma are often picked up through screening tests or genetic testing before symptoms start, which is why relatives are commonly evaluated even if they feel well.
Types of Hereditary pheochromocytoma-paraganglioma
Hereditary pheochromocytoma-paraganglioma has several well-established genetic variants. Each variant involves changes in specific genes that influence where tumors form, how active they are in releasing stress hormones, and the chance of spread. People may notice different sets of symptoms depending on their situation. Knowing the types of hereditary pheochromocytoma-paraganglioma can help you and your care team understand likely tumor locations and plan tailored screening.
SDHB-associated
Often linked to paragangliomas in the abdomen or chest. These tumors may be less likely to cause high-adrenaline symptoms but carry a higher risk of spread. Regular whole‑body imaging is usually emphasized.
SDHD-associated
Typically causes multiple head and neck paragangliomas, sometimes along with adrenal tumors. These often release little or no adrenaline, so symptoms may be subtle like hearing changes or a neck mass. Tumors tend to appear earlier when the variant is inherited from the father.
SDHC-associated
Most often tied to single head and neck paragangliomas. Hormone surges are uncommon, so high blood pressure spikes are less frequent. Overall risk of spread is lower than with SDHB.
SDHAF2-associated
Strongly linked to multiple head and neck paragangliomas. Tumors are usually not adrenaline‑secreting, so symptoms can be local pressure, ringing in the ear, or voice changes. Inheritance from the father is typically required for tumor development.
SDHA-associated
Can present with adrenal or extra‑adrenal paragangliomas, sometimes later in adulthood. Hormone release varies, so some people have classic episodes of pounding headaches, sweating, and palpitations while others do not. Risk of spread appears intermediate.
VHL-related
Part of von Hippel–Lindau syndrome, with adrenal pheochromocytomas more common than paragangliomas. Tumors often release adrenaline, causing episodic headaches, sweating, and rapid heartbeat. Screening also looks for kidney, pancreatic, and eye findings.
RET-related
Seen in multiple endocrine neoplasia type 2 (MEN2). Adrenal pheochromocytomas are common and often bilateral, with clear adrenaline‑type symptoms. Care plans also consider the thyroid because medullary thyroid cancer risk is central in this variant.
NF1-related
Occurs in neurofibromatosis type 1, with adrenal pheochromocytomas more typical than paragangliomas. Adrenaline surges can cause sustained or episodic high blood pressure. Skin findings and nerve‑related tumors help distinguish this variant.
MAX-associated
Tends to cause adrenal tumors that may occur on both sides. Hormone release is common, so people may have classic adrenaline symptoms. Family patterns can be variable, so targeted testing guides screening of relatives.
TMEM127-associated
Usually linked to adrenal pheochromocytomas, often in adulthood. Hormone secretion varies, with some experiencing mild or no symptoms until a routine scan finds a tumor. The overall risk of spread is lower than SDHB.
FH-associated
Rarely, changes in the FH gene are tied to paragangliomas, sometimes alongside skin or uterine fibroids. Hormone secretion is variable, so symptoms range from none to noticeable adrenaline episodes. Management often includes attention to kidney health.
EGLN1/PHD2-associated
Uncommon cause of paragangliomas or pheochromocytomas. Tumors may or may not secrete hormones, and some people have a history of low oxygen states. Because this is rare, plans are individualized by experienced centers.
Factors across types
Not everyone will experience every type. Age at first tumor, hormone release, number of tumors, and risk of spread can differ by variant. Discussing the specific gene can clarify the types of hereditary pheochromocytoma-paraganglioma most relevant to you.
What genetics can tell you about symptoms
Changes in SDHB, SDHD, SDHC, SDHA, or SDHAF2 genes can trigger adrenal or extra-adrenal tumors that release bursts of adrenaline-like hormones, causing pounding headaches, palpitations, sweating, and high blood pressure. SDHB variants more often lead to abdominal tumors and higher spread risk.
Causes and risk factors
Hereditary pheochromocytoma-paraganglioma is caused by an inherited gene change, most often in an SDHx gene. Doctors distinguish between risk factors you can change and those you can’t. Key risk factors for hereditary pheochromocytoma-paraganglioma are a family history and carrying the gene change. Living at high altitude or having long-term low oxygen exposure may raise tumor risk. Risk also varies by gene, and for some genes tumors are more likely when the change comes from the father.
Environmental and biological risk factors
Living with hereditary pheochromocytoma-paraganglioma, it’s natural to ask what in your body or surroundings could make tumors more likely to show up or be noticed. These influences are fewer than many expect, but a handful of internal and environmental factors can raise the odds or shift timing. That said, biology and environment work hand in hand. These factors don’t change early symptoms of hereditary pheochromocytoma-paraganglioma, but they can affect when tumors develop or are detected.
Living above about 1,500–2,500 meters (5,000–8,200 feet) reduces oxygen levels in the body. Over time, this can stimulate oxygen-sensing tissues to grow. In hereditary pheochromocytoma-paraganglioma, that response may increase the chance that paragangliomas form.
Long-standing low blood oxygen from cyanotic congenital heart disease or similar conditions can push oxygen-sensing cells to enlarge. This biological pressure may make paragangliomas more likely. The effect builds over time when oxygen stays low.
Repeated drops in oxygen during sleep may activate pathways that encourage growth in oxygen-sensing tissues. Some studies suggest this pattern could raise the risk of head-and-neck paragangliomas. Research is ongoing to clarify how strong this link is.
Hormonal surges and increased blood flow during pregnancy can unmask or speed tumor growth. For many, this is when a previously silent tumor is first detected. Careful monitoring is often used in this setting.
Genetic risk factors
Inherited changes in several genes drive most cases and can be passed from parent to child. In Hereditary pheochromocytoma-paraganglioma, the exact gene involved shapes which tumors appear, at what age, and how often they recur. Carrying a genetic change doesn’t guarantee the condition will appear. Testing panels that include SDHB, SDHD, SDHC, SDHA, SDHAF2, MAX, TMEM127, VHL, RET, and NF1 can clarify personal and family risk and guide screening.
Runs in families: A single inherited variant can raise risk in each generation. Each child of someone who carries it has about a 50% chance to inherit the same change. This pattern is typical of Hereditary pheochromocytoma-paraganglioma.
Variable risk: Not everyone with a variant develops tumors. This can delay early symptoms of Hereditary pheochromocytoma-paraganglioma or lead to milder disease. Risk often increases with age and differs by gene.
Paternal inheritance: SDHD and SDHAF2 changes usually cause disease when passed down by the father. The same change from the mother often stays silent. Families may see many head-and-neck tumors when this effect is present.
SDHB variants: Raise the chance of paragangliomas outside the head and neck and carry a higher risk of spread. Tumors may occur at younger ages and can be multiple. SDHB is a common cause of Hereditary pheochromocytoma-paraganglioma.
SDHD variants: Often lead to multiple head-and-neck paragangliomas, especially with paternal transmission. Adrenal tumors can occur but are less common.
SDHC variants: Mainly linked to single head-and-neck paragangliomas. Overall lifetime risk is generally lower than with SDHB or SDHD.
SDHA variants: Can predispose to pheochromocytoma or paraganglioma with later onset and lower overall risk. Some carriers never develop tumors.
SDHAF2 variants: Strongly associated with multiple head-and-neck paragangliomas when inherited from the father. Adrenal tumors are uncommon. Onset is often in adolescence or early adulthood.
MAX variants: Often cause adrenal pheochromocytomas, sometimes on both sides. Some families also develop paragangliomas.
TMEM127 variants: Usually linked to adrenal pheochromocytomas that may be multiple or recur. Paragangliomas can occur but are less frequent. These changes contribute to Hereditary pheochromocytoma-paraganglioma in a subset of families.
VHL variants: Part of von Hippel–Lindau syndrome, which includes adrenal pheochromocytoma risk. People may be diagnosed young, and tumors can affect both adrenal glands. Family testing helps define Hereditary pheochromocytoma-paraganglioma risk.
RET variants: Cause multiple endocrine neoplasia type 2 with high pheochromocytoma risk. Tumors often affect both adrenal glands. Identifying RET explains Hereditary pheochromocytoma-paraganglioma in some families.
NF1 variants: Neurofibromatosis type 1 can include pheochromocytoma, usually in adulthood. Overall risk is lower than in VHL or RET conditions.
FH variants: Rare changes in fumarate hydratase may predispose to paraganglioma. Families can also have kidney cancer or skin bumps, which can guide genetic evaluation. This cause of Hereditary pheochromocytoma-paraganglioma is uncommon.
EPAS1 variants: Changes in HIF2A can predispose to paraganglioma or pheochromocytoma, sometimes with high red blood cell counts. Some are mosaic, so only part of the body carries the change. Specialized testing may be needed to find it.
New or mosaic variants: A change can arise for the first time in a child even when parents test negative. Mosaicism can make blood tests miss the change, and tumor testing can help. The variant can still be passed to the next generation.
Family history: Several relatives with pheochromocytoma or paraganglioma strongly suggests a hereditary cause. Clusters across generations point toward Hereditary pheochromocytoma-paraganglioma.
Common in ancestry: Certain regions or ancestries have recurring SDHx or other variants. Knowing this can focus testing and explain why Hereditary pheochromocytoma-paraganglioma is more frequent in some communities.
Lifestyle risk factors
This condition is inherited; lifestyle habits do not cause it, but they can influence symptom flares, blood pressure swings, and treatment safety. In practical terms, how lifestyle affects Hereditary pheochromocytoma-paraganglioma is mostly about avoiding triggers of catecholamine surges and managing factors that destabilize blood pressure. The following lifestyle risk factors for Hereditary pheochromocytoma-paraganglioma focus on elements you can adjust to reduce crises and complications. Always individualize changes with your care team, especially around testing, alpha-blockade, and surgery.
Short, maximal, or heavy isometric efforts can provoke catecholamine release and sudden blood pressure spikes. Favor moderate, steady aerobic activity and avoid maximal exertion unless cleared by your clinician.
Coffee, energy drinks, nicotine, and recreational stimulants can amplify tachycardia and trigger hypertensive episodes. Limiting or avoiding these can reduce palpitations and crisis risk.
Alcohol can precipitate blood pressure surges and palpitations in tumor-related catecholamine excess. It may also worsen dizziness or hypotension when on alpha-blockade, so avoid binge drinking and use caution.
Excess salt can aggravate hypertension before tumors are controlled. Adjust sodium with your team, as salt may be increased temporarily after alpha-blockade but can be harmful beforehand.
Risk prevention
Hereditary pheochromocytoma-paraganglioma is inherited, so you can’t prevent the genetic change itself, but you can lower the chance of dangerous hormone surges and catch tumors early. Prevention works best when combined with regular check-ups. A structured plan—screening, healthy routines, and planning around surgery or pregnancy—can reduce complications. Knowing early symptoms of hereditary pheochromocytoma-paraganglioma, like sudden pounding headaches, racing heart, and sweating, also helps you act quickly.
Meet with a genetics team to confirm your gene change and understand your personal risks. They can guide when to start screening and which relatives may benefit from testing.
Regular blood or urine checks for metanephrines can flag hormone-making tumors before they cause crises. Periodic MRI scans (head/neck through pelvis) help find tumors early without extra radiation.
Monitor blood pressure at home and during visits, since sudden spikes can signal a tumor releasing stress hormones. Watch for bursts of headache, palpitations, sweating, or tremor and seek care.
Avoid stimulant drugs and certain decongestants that can raise blood pressure or trigger hormone release. Always check with your doctor or pharmacist before starting a new medicine or supplement.
Transmission
Hereditary pheochromocytoma-paraganglioma is not infectious; you can’t catch it or pass it to others through everyday contact, coughing, sex, or shared items. Most cases are inherited in a dominant pattern (autosomal dominant): if a parent carries the gene change, each child has a 50% chance of inheriting it. The gene change can come from either the mother or the father, and in some people it appears for the first time with no family history (a new mutation). Not everyone who inherits the change will develop tumors, so the genetic transmission of Hereditary pheochromocytoma-paraganglioma brings a variable level of risk, and understanding how Hereditary pheochromocytoma-paraganglioma is inherited can be important for families.
When to test your genes
Consider genetic testing if you or close relatives had pheochromocytoma or paraganglioma at any age, multiple tumors, bilateral adrenal tumors, or disease before 45. Testing is also reasonable for metastatic, recurrent, or head-and-neck paragangliomas, or if imaging/biochemistry strongly suggests these tumors. Results can guide surveillance, treatment choices, and family screening.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like sudden pounding headaches or spells of racing heart with dizziness. Doctors confirm what’s causing these episodes by combining symptom review, targeted lab tests, and imaging. Early and accurate diagnosis can help you plan ahead with confidence. When hereditary pheochromocytoma-paraganglioma is suspected, the diagnosis is refined with genetic testing and careful assessment of you and your family.
Providers look for classic adrenaline-type spells such as headaches, sweating, palpitations, and sudden high blood pressure. Some paragangliomas make no hormones, so symptoms can be subtle or absent. Exam findings may include blood pressure changes when standing or a neck/abdominal mass.
A three-generation family review helps spot patterns of tumors at younger ages or in multiple relatives. Family history is often a key part of the diagnostic conversation. This can raise suspicion for hereditary pheochromocytoma-paraganglioma and guide testing.
Blood plasma free metanephrines or 24-hour urine metanephrines check for excess hormones from these tumors. Elevated levels support the diagnosis of pheochromocytoma or a secreting paraganglioma. Results also help prioritize which imaging tests to do next.
MRI or CT of the abdomen, pelvis, chest, and neck looks for tumors and their size and location. Functional imaging such as MIBG or PET scans can highlight active tumor tissue. The choice depends on tumor location, prior results, and availability.
Stages of Hereditary pheochromocytoma-paraganglioma
Hereditary pheochromocytoma-paraganglioma does not have defined progression stages. Tumors can appear at different times and in different places, and their behavior varies from person to person rather than following a fixed sequence. Some tumors stay small and quiet for years, while others cause hormone surges or, less commonly, spread to other sites. Because of this variability, doctors focus on ongoing risk and surveillance instead of “stage 1 to stage 4.”
Diagnosis usually combines symptom review (for example, early symptoms of hereditary pheochromocytoma-paraganglioma may include pounding headaches, racing heart, sweating, or high blood pressure spikes), blood or urine tests for specific hormone byproducts, and imaging such as MRI or CT. Genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Looking ahead can feel daunting, but most people with hereditary pheochromocytoma–paraganglioma (Hereditary pheochromocytoma-paraganglioma) can do well with careful, lifelong follow-up. Tumors are usually benign, but they can still cause problems by releasing stress hormones that spike blood pressure, trigger pounding headaches, or lead to sweating spells. Early care can make a real difference, because treating hormone surges and removing or ablating tumors before they spread lowers the risk of complications like stroke or heart rhythm issues.
The outlook is not the same for everyone, but a small percentage of people develop metastatic disease, where tumor cells spread to other parts of the body. Risk varies by the specific gene change, tumor location, and how much hormone the tumor makes; in medical terms, the long-term outlook is often shaped by both genetics and lifestyle. When spread does happen, survival depends on how extensive it is and how well treatments control growth and hormones; many live for years with modern options such as surgery, targeted radiation, and newer systemic therapies. Doctors call this the prognosis—a medical word for likely outcomes.
With ongoing care, many people maintain normal daily routines—working, exercising with guidance, and planning families—with periodic scans and lab tests to watch for new or returning tumors. Because new tumors can appear over time, plan on lifelong surveillance; this helps catch early symptoms of Hereditary pheochromocytoma-paraganglioma before they cause dangerous blood pressure spikes. Families often want to know what role they can play.. If you’re unsure about your personal risk, genetic testing can sometimes provide more insight into prognosis and can guide screening plans for relatives. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Hereditary pheochromocytoma-paraganglioma can lead to health changes that unfold over years, not just during the first tumor episode. Early symptoms of hereditary pheochromocytoma-paraganglioma can be subtle, but the long-term picture centers on tumor behavior, hormone effects, and risks tied to specific gene variants. Long-term effects vary widely, and not everyone experiences the same pattern or severity. Some features show up in adolescence or early adulthood, while others appear later in life.
People may develop more than one tumor over time, sometimes in different body areas such as the adrenal glands, neck, chest, or abdomen. New tumors can appear years after the first one.
In a subset, tumor cells spread to bone, liver, lungs, or lymph nodes. This risk is higher with certain gene changes (for example, SDHB) and can affect long-term survival.
Hormone-releasing tumors can drive sustained or episodic high blood pressure. Over years, this raises the risk of stroke, heart disease, and kidney strain.
Surges of stress hormones can weaken the heart and trigger abnormal rhythms. Some recover after hormones are controlled, while others develop lasting scarring or cardiomyopathy.
How is it to live with Hereditary pheochromocytoma-paraganglioma?
Living with hereditary pheochromocytoma–paraganglioma often means planning around uncertainty: periodic scans and lab tests, watching for surges of headaches, palpitations, sweating, or spikes in blood pressure, and knowing when to seek urgent care if symptoms flare. Many balance normal routines—work, school, exercise—with practical adjustments like carrying medication, limiting triggers such as extreme stress, and coordinating care with specialists who understand both tumors and hormones. Family members may feel the ripple effects too, from learning the warning signs to considering genetic testing and sharing information across generations. With a clear plan, honest communication, and regular follow-up, many find a steady rhythm that protects health while preserving everyday life.
Treatment and drugs
Treatment for hereditary pheochromocytoma‑paraganglioma focuses on safely controlling hormone surges, removing or shrinking tumors, and long‑term monitoring to catch new growths early. Before any procedure, doctors usually use medicines that block adrenaline‑like effects to steady blood pressure and heart rate; these may include alpha‑blockers first, then beta‑blockers. When feasible, surgery is the main treatment to remove pheochromocytomas or paragangliomas, using careful anesthesia plans to prevent dangerous spikes in blood pressure, while some tumors are treated with targeted radiation (such as stereotactic radiotherapy) or radiopharmaceuticals when surgery isn’t possible or disease has spread. Genetic testing and counseling guide follow‑up plans for you and relatives, and imaging plus lab checks continue over time because new tumors can appear years later. Alongside medical treatment, lifestyle choices play a role, like avoiding triggers of adrenaline surges (severe stress, certain decongestants) and keeping regular follow‑up appointments.
Non-drug treatment
Hereditary pheochromocytoma-paraganglioma often calls for ongoing, non-drug care to keep you safe, spot changes early, and plan procedures at the right time. Non-drug treatments often lay the foundation for safe care and long-term follow-up. Early symptoms of hereditary pheochromocytoma-paraganglioma can be subtle, so structured check-ins help catch problems before they escalate. Your care team will tailor choices to your specific gene change, tumor locations, age, and life plans.
Scheduled imaging and lab checks help detect new or growing tumors before they cause harm. Many plans include annual blood or urine tests for metanephrines and periodic MRI scans based on your gene and age.
Structured programs, like genetic counseling, can help you understand your gene change, screening timelines, and family testing. It also supports decisions about pregnancy and shares options for relatives.
Removing secreting or enlarging tumors is the main non-drug way to control hormones and lower risks. Operations are typically done at experienced centers, sometimes with minimally invasive approaches.
Focused radiation, such as stereotactic radiosurgery or external-beam therapy, can slow or stop growth when surgery is not possible. It is often used for head-and-neck paragangliomas or hard-to-reach tumors.
Your genes may have an impact on how drugs work for you
Genes can change how your body handles medications for hereditary pheochromocytoma–paraganglioma, affecting dose needs, side effects, and whether a drug works well. Pharmacogenetic testing and knowledge of the specific gene (like SDHB or RET) can guide safer, more effective choices.
Pharmacological treatments
Medication often plays a key role before surgery, for long-term control, or when tumors spread. Drugs that target symptoms directly are called symptomatic treatments. Most medications for hereditary pheochromocytoma-paraganglioma aim to block adrenaline-like hormones, protect the heart and blood vessels, and reduce tumor hormone output; others aim to shrink or slow tumors themselves. Your team chooses options based on tumor location, hormone activity, imaging traits, and your genes, such as SDHB.
Phenoxybenzamine or selective options like doxazosin help relax blood vessels and control blood pressure before surgery and in daily management. They lower the risk of dangerous surges during procedures and everyday stress. Common effects include lightheadedness and stuffy nose.
Propranolol or metoprolol control rapid heart rate and tremor once alpha blockade is in place. Using them only after alpha blockers helps prevent a blood pressure spike. Doses are tailored to heart rate and symptoms.
Nifedipine or amlodipine can be added if blood pressure remains high or if alpha blockers aren’t tolerated. They relax arterial muscles to smooth out pressure swings. Ankle swelling and headaches may occur.
This medicine lowers adrenaline production at its source to reduce symptoms and improve surgical safety. It can be added when blood pressure or heart rate stay high despite other drugs. Sleepiness or mood changes can occur, so monitoring helps.
Genetic influences
In hereditary pheochromocytoma-paraganglioma, inherited changes in certain genes raise the chance that tumors will form in the adrenal glands or in nerve-related tissue elsewhere in the body. Family history is one of the strongest clues to a genetic influence. Most families show an autosomal dominant pattern, so each child of someone who carries the change has a 50% chance of inheriting it, yet many who inherit a change never develop tumors. The genes most often involved include SDHB or SDHD, and less often SDHC, SDHA, SDHAF2, VHL, TMEM127, MAX, RET, or NF1; each gene tends to shape where tumors arise and at what age. For example, an SDHB change can be linked with tumors outside the adrenal glands and a higher chance they may spread, while SDHD or SDHAF2 often lead to multiple head-and-neck paragangliomas. Some forms also show a parent-of-origin effect—seen with SDHD or SDHAF2—where the risk of tumors tends to appear when the gene change is inherited from the father. Because the chance of an inherited cause is high, genetic testing for hereditary pheochromocytoma-paraganglioma and discussion with a genetic counselor can confirm the gene involved, tailor screening for early detection, and guide testing for relatives.
Is Hereditary pheochromocytoma-paraganglioma genetic?
Genetics play a central role in hereditary pheochromocytoma-paraganglioma; most cases result from inherited variants in genes like SDHB, SDHD, VHL, RET, or NF1. These variants raise tumor risk, influence where tumors appear, and guide screening. Family testing is recommended.
Pharmacogenetics—how genetics influence drug effects
In hereditary pheochromocytoma-paraganglioma, your inherited gene change does more than confirm the diagnosis—it helps steer treatment and medication choices. Doctors can use your genetic information to guide pre-surgery medicines that block adrenaline-like hormones and decide whether to add a drug like metyrosine for stronger control. Certain gene subtypes (for example, SDHB or other SDHx changes) are tied to tumors that release more “stress hormones,” so the plan and dosing of alpha- and beta‑blockers are adjusted to keep blood pressure steady and reduce symptoms. Genetics also shapes advanced treatment options for hereditary pheochromocytoma-paraganglioma: tumors that take up MIBG on scans may respond to radioactive MIBG therapy, while many SDHx‑related tumors show somatostatin receptors and may be better suited to peptide receptor radionuclide therapy (PRRT). Studies suggest that people with SDHB‑related disease may respond particularly well to the chemotherapy temozolomide. Genes are just one piece of the puzzle; your scans, hormone levels, tumor location, and overall health all help your team tailor safe, effective treatment options for hereditary pheochromocytoma-paraganglioma.
Interactions with other conditions
For people living with hereditary pheochromocytoma-paraganglioma, bursts of stress hormones can interact with other health issues in noticeable ways, especially heart and metabolic conditions. Doctors call it a “comorbidity” when two conditions occur together. High blood pressure, irregular heartbeats, coronary artery disease, and obstructive sleep apnea may all flare when tumors release hormones, and blood sugar control in diabetes can become more difficult. Some inherited forms, particularly those involving SDH gene changes, are also linked with other tumors such as kidney cancer, certain gastrointestinal stromal tumors, and occasionally pituitary tumors, so screening plans often overlap. Because symptoms like pounding heartbeat, sweating, and nervousness can resemble anxiety or an overactive thyroid, early symptoms of hereditary pheochromocytoma-paraganglioma may be overlooked when another condition is active. Certain medicines used for other illnesses—like some antidepressants, stimulants, or beta-blockers taken without an alpha-blocker—can worsen hormone surges, so coordinated care and a careful medication review are important.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden pounding headaches, racing heartbeats, and flushing spells that seemed to strike without warning—episodes we now recognize in some as signs of hereditary pheochromocytoma-paraganglioma. In families, an aunt’s “spells,” a grandfather’s “temper and sweats,” and a cousin’s high blood pressure in their 20s could all be quiet echoes of the same inherited condition. Many living with hereditary pheochromocytoma-paraganglioma felt well between episodes, so early stories often focused on the dramatic moments rather than the underlying cause.
First described in the medical literature as unusual growths of adrenal or nerve-tissue origin, these tumors were once thought to be rare, isolated findings discovered during surgery for severe hypertension. Early physicians connected the dots through symptoms—headache, palpitations, sweating—long before lab tests could measure the hormones involved. As surgical techniques and pathology advanced in the late 19th and early 20th centuries, doctors learned that some tumors sat on the adrenal glands (pheochromocytomas) while others arose along nerve pathways outside the adrenals (paragangliomas).
From early theories to modern research, the story of hereditary pheochromocytoma-paraganglioma has steadily shifted from surprise surgical discoveries to planned, preventive care. Mid-20th-century reports noted striking family patterns: multiple relatives with similar tumors, people developing them at younger ages, or more than one tumor in the same individual. These clues suggested an inherited component. By the late 20th and early 21st centuries, advances in genetics confirmed that changes in certain genes—many affecting the cell’s energy and oxygen-sensing pathways—could be passed down in families, explaining why some people had a higher lifelong risk.
In recent decades, awareness has grown as genetic testing became more accessible. This changed daily life for many families. Instead of waiting for early symptoms of hereditary pheochromocytoma-paraganglioma to appear, relatives could be offered counseling, testing, and regular check-ins. Imaging and blood or urine tests helped find tumors earlier, often before they caused severe blood pressure spikes or other complications. Clinicians also learned that the condition varies: some families tend toward adrenal tumors, others toward head, neck, or chest paragangliomas; some tumors release hormones, others stay “silent” but still need monitoring.
Today, the history informs how care is organized. What started as scattered case reports now supports coordinated, lifelong follow-up that balances vigilance with quality of life. Knowing the condition’s history helps explain why guidelines stress family history, early evaluation, and shared decision-making. It also underscores a key point for people with hereditary pheochromocytoma-paraganglioma and their families: understanding the past has opened the door to earlier detection, tailored treatment, and better outcomes over time.